The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 485)
LRRK2 Biology Consortium, 2018
Parkinson's disease (PD) affects nearly any body system, as evidenced by the diversity of its symptoms. While its non-motor symptoms, such as olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and gastrointestinal (GI) abnormalities, do not define the disease, they have a large impact on those living with it. In this project, we will use a pre-clinical model o...
Researchers: R. Jeremy Nichols, PhD
Biomarkers Across Neurodegenerative Diseases, 2018
This study builds on two recent discoveries in neuroscience: first, the brain is organized in large-scale networks of nerve cells; and second, the clumps of alpha-synuclein, amyloid and tau -- proteins implicated in Parkinson's disease (PD) and Alzheimer's disease (AD) -- can spread from nerve cell to nerve cell, like infection.
Parkinson's and Alzheimer's affect diffe...
Researchers: Alain Dagher, MD
Access to Data and Biospecimens, 2018
Interplay Between Microtubules, Alpha-synuclein and Inflammation as a Clue to Understanding and Managing Parkinson's Disease
Recent research has linked alpha-synuclein, a sticky protein that clumps in the brains of people with Parkinson's disease (PD), and microtubules (cell structure supports) in Parkinson's disease (PD). Microtubules play many important roles in brain cells, supporting the remodeling, maintenance and formation of synapses, structures through which brain cells communicate. Microtubule ...
Researchers: Massimiliano (Max) Bianchi, PhD
Research Grant, 2018
In the past, we demonstrated that using drugs to deactivate Rho-associated protein kinase (ROCK), a protein regulating shape and movement of cells, can protect dopamine-producing brain cells from damage caused by alpha-synuclein, a sticky protein that clumps in the brains of people with Parkinson's disease (PD). However, the optimal drug for ROCK deactivation in PD has not yet bee...
Target Advancement Program, 2018
NFE2L1 is a protein that controls the expression of genes involved in the differentiation and survival of dopamine neurons. NFE2L1 levels are reduced in dopamine neurons in the brains of people with Parknison's disease (PD), and we recently found that a minor alteration of NFE2L1 can lower PD risk. These observations imply that neuron death in PD may result in part from a loss of t...